BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 8178901)

  • 1. Coagulation and anticoagulation effects of contraceptive steroids.
    Samsioe G
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1523-7. PubMed ID: 8178901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemostatic changes and the oral contraceptive pill.
    Norris LA; Bonnar J
    Baillieres Clin Obstet Gynaecol; 1997 Sep; 11(3):545-64. PubMed ID: 9488791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
    Winkler UH; Schindler AE; Endrikat J; Düsterberg B
    Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease.
    Kelleher CC
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):392-5. PubMed ID: 2196811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contraceptive choices in women with coagulation disorders.
    Comp PC; Zacur HA
    Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 2):1990-3. PubMed ID: 8512043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects on hemostasis of oral contraceptives containing desogestrel.
    Stubblefield PG
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1047-52. PubMed ID: 8447359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR; Ory H
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemostatic effects of smoking and oral contraceptive use.
    Fruzzetti F
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S369-74. PubMed ID: 10368523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
    Lachnit-Fixson U
    Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD; Lawrenson RA
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.
    Quehenberger P; Kapiotis S; Pärtan C; Schneider B; Wenzel R; Gaiger A; Speiser W
    Ann Hematol; 1993 Jul; 67(1):33-6. PubMed ID: 8392873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.
    Jespersen J; Petersen KR; Skouby SO
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):396-403. PubMed ID: 2196812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Norgestimate: a clinical overview of a new progestin.
    Bringer J
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.